VC Renaissance: Index Ventures spin off Medicxi launches GSK and J&J backed €210m fund
Biologics developers backed by Medicxi Ventures’ new €210m ($229m) fund will use Lonza for contract manufacturing under an existing deal with Index Ventures.
Archives for February 3, 2016
Sandoz, Pfizer and regulators back biosimilar data extrapolation
Approving a biosimilar for the same diseases as the originator drug based on extrapolated data rather than study results should remain a cornerstone of the review process say regulators and developers.